venBio Partners LLC - Q2 2019 holdings

$225 Million is the total value of venBio Partners LLC's 6 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 50.0% .

 Value Shares↓ Weighting
AKRO NewAKERO THERAPEUTICS INC$75,736,0003,954,858
+100.0%
33.61%
DTIL  PRECISION BIOSCIENCES INC$56,513,000
-26.2%
4,265,1410.0%25.08%
-59.6%
TPTX NewTURNING POINT THERAPEUTICS I$54,549,0001,340,265
+100.0%
24.21%
APLS SellAPELLIS PHARMACEUTICALS INC$25,340,000
-14.8%
1,000,000
-34.5%
11.24%
-53.3%
MNLO  MENLO THERAPEUTICS INC$8,755,000
-23.7%
1,461,5520.0%3.88%
-58.2%
VRNA  VERONA PHARMA PLCsponsored ads$4,463,000
-21.5%
875,0000.0%1.98%
-57.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2020-05-20
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
VERONA PHARMA PLC15Q2 202222.2%
AKERO THERAPEUTICS INC14Q3 202265.3%
ALX ONCOLOGY HLDGS INC13Q3 202373.8%
HARMONY BIOSCIENCES HLDGS IN13Q3 202321.1%
APELLIS PHARMACEUTICALS INC11Q2 202162.0%
PHARVARIS N V11Q3 202325.2%
IMPEL PHARMACEUTICALS INC10Q3 20237.3%
ELEVATION ONCOLOGY INC10Q3 20234.2%
VENTYX BIOSCIENCES INC8Q3 202342.7%
PRECISION BIOSCIENCES INC7Q3 202062.0%

View venBio Partners LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View venBio Partners LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export venBio Partners LLC's holdings